The FDA granted accelerated approval to DS-8201a for patients with unresectable or metastatic HER2-positive BC who have received ≥2 prior anti-HER2-based regimens in the metastatic setting.DS-8201a has been approved for the treatment of adult patients with locally advanced or metastatic HER2-positive GC/GEJC who have received a prior trastuzumab-based therapy regimen. This evidence concerns the gene ERBB2 and breast cancer.